When discussing how long Eylea stays in your system, it’s important to distinguish between how long the drug remains in your eye versus your bloodstream. According to the drug’s prescribing ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58% ...
Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...
Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results